

U.S.S.N. 07/867,819

Filed: April 13, 1992

AMENDMENT AND RESPONSE TO OFFICE ACTION

Remarks

Claims 1-3 and 10-16 have been allowed. The specification has been amended to recite the Sequence Listing numbers, as requested by the Examiner. The Sequence Listing has been amended to include all peptide sequences shown in Figure 1, and does not add any new matter. Applicants enclose a 3 & 1/2" diskette containing a computer-readable form of the Sequence Listing as well as a paper copy of the Sequence Listing. Please replace the Sequence Listing with the corrected 43 pages of Sequence Listing.



U.S.S.N. 07/867,819


Filed: April 13, 1992

AMENDMENT AND RESPONSE TO OFFICE ACTION

Declaration under 37 C.F.R. § 1.821(f)

I declare that the material on the diskette is identical to the enclosed paper copy of the Sequence Listing and the sequences as filed in the application on April 13, 1992, that the Sequence Listing does not add new matter to the application, and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Date: February 29, 2003

HOLLAND & KNIGHT LLP
One Atlantic Center, Suite 2000
1201 West Peachtree Street
Atlanta, Georgia 30309-3400
(404) 817-8473
(404) 817-8588 (Fax)




U.S.S.N. 07/867,819

Filed: April 13, 1992

AMENDMENT AND RESPONSE TO OFFICE ACTION

Certificate of Mailing Under 37 C.F.R. § 1.8(a)

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.



Aisha Wyatt

Date: February 27, 2003



U.S.S.N. 07/867,819

Filed: April 13, 1992

MARKED UP VERSION OF AMENDMENTS PURSUANT TO 37 C.F.R. § 1.121

Marked Up Version of Amended Specification Paragraphs

Pursuant to 37 C.F.R. § 1.121(b)(1)(iii)

-- Figure 1 graphs the antigenic regions of Sm B/B', with the octapeptides binding with an absorbance greater than 0.50, and their surrounding octapeptides. The following octapeptides are studied: IGTFKAFD (SEQ ID NO:103), GTFKAFDK (SEQ ID NO: 1), TFKAFDKH (SEQ ID NO:123), DCDEFRKI (SEQ ID NO:104), CDEFRKIK (SEQ ID NO:124), DEFRRKIKP (SEQ ID NO: 125), EFRKIKPK (SEQ ID NO:126), FRKIKPKN (SEQ ID NO:127), RKIKPKNA (SEQ ID NO:128), KIKPKNAK (SEQ ID NO:129), IKPKNAKQ (SEQ ID NO:130), KPKNAKQP (SEQ ID NO: 131), PKNAKQPE (SEQ ID NO:105), QQVMTPOQG (SEQ ID NO: 107), QVMTPOQGR (SEQ ID NO:132), VMTPQGRG (SEQ ID NO:133), MTPQGRGT (SEQ ID NO: 134), TPQGRGTV (SEQ ID NO: 135), PQGRGTVVA (SEQ ID NO: 136), QGRGTVAA (SEQ ID NO:108), APTQYPPG (SEQ ID NO:109), PTQYPPGR (SEQ ID NO:137), TQYPPGRG (SEQ ID NO:138), QYPPGRGT (SEQ ID NO:139), YPPGRGTP (SEQ ID NO:140), PPGRGTTPP (SEQ ID NO: 141), PGRGTPPP (SEQ ID NO: 142), GRGTPPPP (SEQ ID NO: 143), RGTPPPP (SEQ ID NO: 144), GTTPPPVG (SEQ ID NO:110), IMAPPPGM (SEQ ID NO: 111), MAPPPGMR (SEQ ID NO:145), APPPGMRP (SEQ ID NO:146), PPPGMRPP (SEQ ID NO: 147), PPGMRPPM (SEQ ID NO:148), IGMPPPGM (SEQ ID NO: 112), GMPPPGMR (SEQ ID NO:113), MPPPGMRP (SEQ ID NO: 118), PPPGMRPP (SEQ ID NO: 149), PPGMRPPP (SEQ ID NO:114), MRPPPGI (SEQ ID NO: 115), RPPPPGIR (SEQ ID NO:150), PPPPGIRG (SEQ ID NO:151), PPPGIRGP (SEQ ID NO: 152), PPGIRGPP (SEQ

U.S.S.N. 07/867,819

Filed: April 13, 1992

AMENDMENT AND RESPONSE TO OFFICE ACTION

ID NO: 153), RGPPPGM (SEQ ID NO:154), GPPPGMR (SEQ ID NO: 155), PPPPGMRP

(SEQ ID NO: 156), PPPGMRPP (SEQ ID NO: 157), PPGMRPPR (SEQ ID NO:158)--

ATL1 #560506 v1

